Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendimagegn Ghidey

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Arthritis and Rheumatism|April 21, 2011
The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigensAnnemiek Willemze, Diane van der Woude, Wendimagegn Ghidey, et al.
Haematologica|December 15, 2015
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myelomaAnnemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, et al.
Blood|April 17, 2014
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLLChristian H Geisler, Mars B van T' Veer, Jesper Jurlander, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2010
Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevityMarian Beekman, Christa Nederstigt, H Eka D Suchiman, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Arthritis and Rheumatism|April 21, 2011
The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigensAnnemiek Willemze, Diane van der Woude, Wendimagegn Ghidey, et al.
Haematologica|December 15, 2015
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myelomaAnnemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, et al.
Blood|April 17, 2014
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLLChristian H Geisler, Mars B van T' Veer, Jesper Jurlander, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2010
Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevityMarian Beekman, Christa Nederstigt, H Eka D Suchiman, et al.
Pageof 2